DB:NUG

Stock Analysis Report

Executive Summary

ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease.

Rewards

Earnings are forecast to grow 95.74% per year

Risk Analysis

Has less than 1 year of cash runway

Makes less than USD$1m in revenue (A$24K)

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Exceptional growth potential with excellent balance sheet.

Share Price & News

How has ResApp Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NUG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.9%

NUG

2.3%

DE Healthcare Services

0.07%

DE Market


1 Year Return

190.7%

NUG

32.9%

DE Healthcare Services

14.8%

DE Market

Return vs Industry: NUG exceeded the German Healthcare Services industry which returned 33% over the past year.

Return vs Market: NUG exceeded the German Market which returned 17.1% over the past year.


Shareholder returns

NUGIndustryMarket
7 Day1.9%2.3%0.07%
30 Day13.8%1.0%1.9%
90 Day-29.9%12.7%7.1%
1 Year190.7%190.7%34.1%32.9%18.4%14.8%
3 Year-27.7%-27.7%68.6%64.3%17.4%7.0%
5 Yearn/a196.3%183.2%27.9%10.4%

Price Volatility Vs. Market

How volatile is ResApp Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ResApp Health undervalued compared to its fair value and its price relative to the market?

24.35x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NUG's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NUG's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NUG is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: NUG is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NUG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NUG is overvalued based on its PB Ratio (23.4x) compared to the DE Healthcare Services industry average (2.6x).


Next Steps

Future Growth

How is ResApp Health forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

95.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NUG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: NUG is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NUG's is expected to become profitable in the next 3 years.

Revenue vs Market: NUG's revenue (94.4% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: NUG's revenue (94.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NUG's Return on Equity is forecast to be very high in 3 years time (70.3%).


Next Steps

Past Performance

How has ResApp Health performed over the past 5 years?

-33.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NUG is currently unprofitable.

Growing Profit Margin: NUG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NUG is unprofitable, and losses have increased over the past 5 years at a rate of -33.7% per year.

Accelerating Growth: Unable to compare NUG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NUG is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (27.6%).


Return on Equity

High ROE: NUG has a negative Return on Equity (-70.76%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is ResApp Health's financial position?


Financial Position Analysis

Short Term Liabilities: NUG's short term assets (A$7.5M) exceed its short term liabilities (A$1.7M).

Long Term Liabilities: NUG's short term assets (A$7.5M) exceed its long term liabilities (A$39.7K).


Debt to Equity History and Analysis

Debt Level: NUG is debt free.

Reducing Debt: NUG has not had any debt for past 5 years.


Balance Sheet

Inventory Level: NUG has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if NUG's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NUG has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NUG has less than a year of cash runway if free cash flow continues to reduce at historical rates of -21% each year


Next Steps

Dividend

What is ResApp Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.5%industryaverage1.5%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate NUG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NUG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NUG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NUG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NUG's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of ResApp Health's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average board tenure


CEO

Tony Keating 0

4.5yrs

Tenure

AU$290,039

Compensation

Dr. Anthony Keating, also known as Tony, has been Chief Executive Officer and Managing Director of ResApp Health Limited since July 2, 2015. Dr. Keating served as a Director of Commercial Engagement for En ...


CEO Compensation Analysis

Compensation vs Market: Tony's total compensation ($USD200.16K) is below average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.


Board Age and Tenure

2.3yrs

Average Tenure

Experienced Board: NUG's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.


Management Team

  • Clas Källander

    Founder and Director of R&D of Cavidi AB

    • Compensation: AU$108.72k
  • Nicki Farley (43yo)

    Company Secretary

    • Tenure: 7.2yrs
  • Tony Keating

    CEO, MD & Director

    • Tenure: 4.5yrs
    • Compensation: AU$290.04k
  • Brian Leedman

    Vice President of Corporate Affairs

    • Compensation: AU$190.18k
  • Udantha Abeyratne

    Chief Scientist & Scientific Advisor

    • Paul Porter

      Scientific Advisor

      • Kay Taylor

        Vice President of Strategic Development & Operations


        Board Members

        • Roger Aston (63yo)

          Non-Executive Chairman

          • Tenure: 4.5yrs
          • Compensation: AU$90.00k
        • Joe Kvedar

          Member of Industry Advisory Board

          • Tenure: 0.6yrs
        • Nathan Edmund Buzza

          Non-Executive Director

          • Tenure: 2.1yrs
          • Compensation: AU$55.00k
        • Chris Ntoumenopoulos

          Non-Executive Director

          • Tenure: 5yrs
          • Compensation: AU$55.00k
        • Naomi Fried

          Member of Industry Advisory Board

          • Tenure: 0.6yrs
        • Tony Keating

          CEO, MD & Director

          • Tenure: 4.5yrs
          • Compensation: AU$290.04k
        • Udantha Abeyratne

          Chief Scientist & Scientific Advisor

          • Paul Porter

            Scientific Advisor

            • Philip Currie

              Member of Scientific Advisory Board

              • Tenure: 2.4yrs
            • Scott Claxton

              Member of Scientific Advisory Board

              • Tenure: 1yrs

            Company Information

            ResApp Health Limited's company bio, employee growth, exchange listings and data sources


            Key Information

            • Name: ResApp Health Limited
            • Ticker: NUG
            • Exchange: DB
            • Founded: 2014
            • Industry: Health Care Technology
            • Sector: Healthcare
            • Market Cap: AU$187.989m
            • Listing Market Cap: AU$116.572m
            • Shares outstanding: 696.26m
            • Website: https://www.resapphealth.com.au

            Location

            • ResApp Health Limited
            • 100 Creek Street
            • Level 12
            • Brisbane
            • Queensland
            • 4000
            • Australia

            Listings

            TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
            RAPASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2005
            RAPCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2005
            NUGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2005

            Biography

            ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company delivers mobile software apps in various clinical settings, including telehealth, emergency, urgent care, and primary care. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was founded in 2014 and is headquartered in Brisbane, Australia. 


            Company Analysis and Financial Data Status

            All financial data provided by Standard & Poor's Capital IQ.
            DataLast Updated (UTC time)
            Company Analysis2020/01/18 21:55
            End of Day Share Price2020/01/17 00:00
            Earnings2019/06/30
            Annual Earnings2019/06/30


            Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.